Expression of growth factors in brain tumors: Correlation with tumor grade, recurrence and survival

Clinical Neuropathology

Volumn 29, Issue 2, 2010, Pages 109-114

  Maiuri, F ^a   De Del Basso Caro, M ^b   Siciliano, A ^b   Peca, C ^a   Vergara, P ^a   Mariniello, G ^a   Pettinato, G ^b  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

Brain tumor; Ependymoma; Glioma; Growth factor

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; GROWTH FACTOR; PLATELET DERIVED GROWTH FACTOR; PROTEIN P53; TENASCIN; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 1; TRANSFORMING GROWTH FACTOR BETA1; TRANSFORMING GROWTH FACTOR BETA2; TRANSFORMING GROWTH FACTOR BETA3; VASCULOTROPIN;

ADOLESCENT; ADULT; AGED; ARTICLE; ASTROCYTOMA; BRAIN SURGERY; BRAIN TUMOR; CANCER GRADING; CANCER SURVIVAL; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; EPENDYMOMA; FEMALE; GLIOBLASTOMA; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; MALIGNANT TRANSFORMATION; OLIGODENDROGLIOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECURRENCE RISK; REOPERATION; TUMOR RECURRENCE;

EID: 77951012988     PISSN: 07225091     EISSN: None     Source Type: Journal    
DOI: 10.5414/npp29109     Document Type: Article

References (33)

1. Cunningham JM, Kimmel DW, Scheithauer BW, O'Fallon JR, Novotny PJ, Jenkins MD. Analysis of proliferation markers and p53 expression in gliomas of astrocytic origin: relationship and prognostic value. J Neurosurg. 1997; 86: 121-130.
2. Hamel W, Westphal M. Growth factors in gliomas revisited. Acta Neurochir. 2000; 142: 113-138.
3. Machein MR, Plate KH. VEGF in brain tumors. J Neuro-oncol. 2000; 50: 109-120.
4. Korshunov A, Golanov A, Sycheva R. Immunohistochemical markers for prognosis of oligodendroglial neoplasms. J Neuro-oncol. 2002; 58: 237-253, 255-270. (Pubitemid 34830636)
5. Jensen RL. Growth factor-mediated angiogenesis in the malignant progression of glial tumors: a review. Surg. Neurol. 1998; 49: 189-195.
6. Merril MG, Oldfield EH. A reassement of vascular endothelial growth factor in central nervous system pathology. J Neurosurg. 2005; 103: 853-868. (Pubitemid 43194580)
7. Abdulrauf SI, Edvardesen K, Ho KL, Yang XY, Rock JP, Rosenblum ML. Vascular endothelial growth factor expression and vascular density as prognostic markers of survival in patients with low-grade astrocytoma. J Neurosurg. 1998; 88: 513-520.
8. Oehring RD, Miletic M, Valter MM, Pietsch T, Neumann J, Fimmers R, Schlegel U. Vascular endothelial growth factor (VEGF) in astrocytic gliomas - a prognostic factor? J Neuro-oncol. 1999; 45: 117-125.
9. Gran SJ, Trillsch F, Herms J, Thon N, Nelson PJ, Tonn JC, Goldbrunner R. Expression of VEGFR3 in glioma endothelial correlates with tumor grade. J Neuroncol. 2007; 82: 141-151. (Pubitemid 46431856)
10. Kawataki T, Naganuma H, Sasaki A, Yoshikawa H, Tasaka K, Nukui H. Correlation of thrombospondin-1 and transforming growth factor-β expression with malignancy of glioma. Neuropathology. 2000; 20: 161-169. (Pubitemid 32963612)
11. Schneider T, Sailer M, Insorge S, Firshing R, Reinhold D. Increased concentrations of transforming growth factor β1 and β2 in the plasma of patients with glioblastoma. J Neuro-oncol. 2006; 79: 61-65. (Pubitemid 44057419)
12. Smits A, Funa K. Platelet-derived growth factor (PDGF) in primary brain tumors of neuroglial origin. Histol Histopathol. 1998; 13: 511-520. (Pubitemid 28197714)
13. Hurtt MR, Moosey J, Donovan-Peluso M, Cocker J. Amplification of EGFR gene in gliomas: histopathology and prognosis. J Neuropathol. Exp. Neurol. 1992; 51: 84-90.
14. Stark AM, Witzel P, Strege RJ, Hugo HH, Mehdorn HM. p53, mdm2, EGFR and msh2 expression in paired initial and recurrent glioblastoma multiforme. J Neurol Neurosurg Psychiatry. 2003; 74: 779-783. (Pubitemid 36628293)
15. Aldape KD, Ballman K, Furth A, Buckuer JC, Giannini C, Burger PC, Scheithauer BW, Jenkins RB, James CD. Immunohistochemical detection of EGFRvIII in high malignancy grade astrocytomas and evaluation of prognostic significance. J Neuropathol. Exp. Neurol. 2004; 63: 700-707. (Pubitemid 38891086)
16. Heimberger AB, Hlatky R, Suki D, Yang D, Weinberg J, Gilbert M, Sawaya R, Aldape K. Prognostic effect of epidermal growth factor and EGFRvIII in glioblastoma multiforme patients. Clin Cancer Res. 2005; 17: 1462-1466. (Pubitemid 40315227)
17. Quann AL, Barnett GH, Lee SY, Vogelbann MA, Tons SA, Stangaitis SM, Prayson RA. Epidermal growth factor receptor amplification does not have prognostic significance in patients with glioblastoma multiforme. Int J Radiat. Oncol. Biol. Physiol. 2005; 63: 695-703. (Pubitemid 41400054)
18. Vaquero J, Zurita M, Coca S, Oya S, Morales C. Prognostic significance of clinical and angiogenesis-related factors in low-grade oligodendroglioma. Surg. Neurol. 2000; 54: 229-234.
19. Korshunov A, Golanov A. The prognostic significance of vascular endothelial growth factor (VEGF C-1) immunoexpression in oligodendroglioma. An analysis of 91 cases. J Neuro-oncol. 2000; 48: 13-19.
20. Reinferberg Q, Ring GU, Gies U. Analysis of p53 mutation and epidermal growth factor receptor amplification in recurrent gliomas with malignant progression. J Neuropathol. Exp. Neurol. 1996; 55: 822-831. (Pubitemid 26238584)
21. Reis-Filho JS, Faoro LN, Carrilho C, Bleggi-Torres LF, Schmitt FC. Evaluation of cell proliferation, epidermal growth factor receptor, and bcl-2 immunoexpression as prognostic factors for patients with World Health Organization Grade II oligodendroglioma. Cancer. 2000; 88: 862-869. (Pubitemid 30091106)
22. Di Rocco F, Carrol RS, Zhang J, Black PM. Plateled-derived growth factor and its receptor expression in human oligodendrogliomas. Neurosurgery 1998; 42: 341-346. (Pubitemid 28076794)
23. Smith JS, Wang XY, Qian J, Kosek SM, Scheithauer BW, Jenkins R, James CD. Amplification of platelet-derived growth factor receptor- (PDGFRA) gene occurs in oligodendrogliomaswith Grade IV anaplastic features. J Neuropathol. Exp Neurol. 2000; 59: 495-503. (Pubitemid 30368309)
24. Robinson S, Cohen M, Prayson R, Ransohoff R, Tabrizi N, Miller RH. Constitutive expression of growth-related oncogene and its receptor in oligodendrogliomas. Neurosurgery. 2001; 48: 864-874. (Pubitemid 32268096)
25. Maiuri F, Del Basso De Caro ML, Iaconetta G, Peca C, Esposito M, de Divitiis E. Prognostic and survival-related factors in patients with well-differentiated oligodendrogliomas. Zentralbl Neurochir. 2006; 67: 204-209. (Pubitemid 44951682)
26. Hall WA, Merril LMJ, Walbridje S, Youle RJ. Epidermal growth factor receptors in ependymomas and other brain tumors. J Neurosurg. 1990; 72: 641-646. (Pubitemid 20113693)
27. Diedrich U, Lucius J, Baron E, Behnke J, Pabst B, Zoll V. Distribution of epidermal growth factor receptor gene amplification in brain tumours and correlation to prognosis. J Neurol. 1995; 242: 638-688.
28. Black P, Carroli R, Glowacka D. Expression of platelet-derived growth factor transcripts in medulloblastomas and ependymomas. Pediatr Neurosurg. 1996; 24: 74-78. (Pubitemid 26226236)
29. Fink KL, Rushing EJ, Schold SC, Nisen PD. Infrequency of p53 gene mutation in ependymomas. J Neuro-oncol. 1996; 27: 111-115. (Pubitemid 26052645)
30. Pietsch T, Valter MM, Wolf HK, von Deimling A, Huang HJ, Cavenee WK, Wiestler OD. Expression and distribution of vascular and endothelial growth factor protein in human brain tumors. Acta Neuropathol. 1997; 93: 109-117. (Pubitemid 27060902)
31. Kramer DL, Parmiter AH, Rorke LB. Molecular cytogenic studies of pediatric ependymomas. J Neuro-oncol. 1998; 37: 25-33.
32. Korshunov A, Golanov A, Timirgaz V. Immunohistochemical markers for intracranial ependymoma recurrence. An analysis of 88 cases. J Neurol. Sci. 2000; 177: 72-82.
33. Korshunov A, Golanov A, Timirgaz V. Iimmunohystochemical markers for prognosis of ependymal neoplasm. J Neuro-oncol 2002; 58: 255-270. (Pubitemid 34830636)